… untreated patients with unresectable or metastatic urothelial carcinoma, … Nivolumab is an
antibody directed against programmed … of patients with locally advanced or metastatic urothelial …

… evidence of metastatic or surgically unresectable, locally advanced urothelial carcinoma; …
metastatic disease were included. Additional eligibility criteria were reported previously (2). …

… SOC) for cis-eligible patients (pts) with unresectable/metastatic urothelial carcinoma (mUC)
for decades… We report results for nivolumab (NIVO) plus gemcitabine-cis (GC) or GC alone in …

… were ≥18 yr old with histologically confirmed UC with metastatic or unresectable, locally
advanced measurable disease (RECIST v1.1) and Eastern Cooperative Oncology Group …

… in previously untreated patients with unresectable, locally advanced or metastatic … using
nivolumab + ipilimumab as an immunotherapeutic boost for metastatic urothelial carcinoma? …

… , including cohorts for urothelial carcinoma, RCC, and other rare GU tumors with no standard
treatment options, and has also led to larger trials in GU tumors, including CheckMate 9ER (…

… Nivolumab (nivo) 1mg/kg plus ipilimumab (ipi) 3mg/kg achieved the highest ORR (42.4%)
in refractory metastatic urothelial carcinoma … in patients with unresectable urothelial cancer …

… CheckMate 275 was a single-arm phase II study of nivolumab in patients with platinum-refractory
metastatic UC [41]. The study endpoint was ORR in the overall group and the …

… to the treatment landscape of bladder cancer. Nivolumab is an immune checkpoint inhibitor
… of platinum-refractory locally advanced or metastatic urothelial carcinoma. More recently, it …

… We aimed to examine the safety and activity of nivolumab … -line treatment for patients with
metastatic urothelial carcinoma. … in patients with locally advanced or metastatic urothelial …